Fig. 3: IFNγ and IL-17 cooperate for aged host αPD-L2 efficacy against B16 melanoma.

a Flow cytometry UMAP color-continuous overlays of overall tumour-infiltrating CD45⁺ immune cell density, IFNγ⁺ CD45⁺ tumour-infiltrating immune cells, and IL-17⁺ CD45⁺ tumour-infiltrating immune cells in wild type aged (isotype n = 4 mice, αPD-L2 n = 4 mice), wild type young (isotype n = 5 mice, αPD-L2 n = 4 mice), and IL-17^KO aged mice (isotype n = 5 mice, αPD-L2 n = 4 mice) challenged subcutaneously with B16 murine melanoma and treated with αPD-L2 (200 µg/mouse) or isotype control (200 µg/mouse) intraperitoneally every 4 days starting on day 3. b Prevalence of IFNγ⁺ CD45⁺, c IFNγ⁺ CD8⁺ and d IFNγ⁺ CD4⁺ tumour-infiltrating immune cells in isotype or αPD-L2 treated young or aged mice as indicated. e Mean fluorescence intensity (MFI) of IFNγ in CD45⁺, f CD8⁺ and g CD4⁺ tumour-infiltrating immune cells in isotype or αPD-L2 treated young or aged mice as indicated. h Prevalence of IL-17⁺ CD45⁺ tumour-infiltrating immune cells in isotype or αPD-L2 treated young or aged mice as indicated. i MFI of IL-17 in CD45⁺ tumour-infiltrating immune cells in isotype or αPD-L2 treated young or aged mice as indicated. Standard error of mean indicated; p-values by unpaired Student’s t-test.